Creative Medical Technology Holdings, Inc.
CELZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001187953
No open-market purchases or sales by Creative Medical Technology Holdings, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $540.7K in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Creative Medical Technology Holdings, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +1 vs. Q3 2022
- Shares held
- 413.3K
- −175.7K (−29.8%) vs. Q3 2022
- Total value
- $156.1K
- −$100.9K (−39.3%) vs. Q3 2022
- New holders
- 5
- 2 more added
- Sold out
- 4
- 3 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CELZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $540.7K |
| Q1 2026 | 11 | $199.3K |
| Q4 2025 | 14 | $252.6K |
| Q3 2025 | 12 | $233.4K |
| Q2 2025 | 12 | $185.4K |
| Q1 2025 | 11 | $437.1K |
| Q4 2024 | 8 | $71.2K |
| Q3 2024 | 10 | $213.8K |
| Q2 2024 | 9 | $267.0K |
| Q1 2024 | 13 | $551.9K |
| Q4 2023 | 8 | $90.4K |
| Q3 2023 | 8 | $104.3K |
| Q2 2023 | 9 | $96.4K |
| Q1 2023 | 15 | $175.5K |
| Q4 2022 | 19 | $156.1K |
| Q3 2022 | 18 | $257.0K |
| Q2 2022 | 15 | $1.13M |
| Q1 2022 | 15 | $734.0K |
| Q4 2021 | 10 | $575.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Creative Medical Technology Holdings, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Advisor Group Holdings, Inc. | 12 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 1 | $0 | 0.00% | +1 | New |
| Wells Fargo & Company | 96 | $37 | 0.00% | +3+3.2% | Added |
| Morgan Stanley | 200 | $76 | 0.00% | +200 | New |
| Bank of America Corp | 1,075 | $410 | 0.00% | 00.0% | Unchanged |
| US Bancorp | 3,000 | $1.14K | 0.00% | 00.0% | Unchanged |
| Perkins Capital Management Inc | 10,000 | $4.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 9,230 | $4.00K | 0.00% | −256−2.7% | Reduced |
| StoneX Group Inc. | 15,000 | $5.72K | 0.00% | +15,000 | New |
| Northern Trust Corp | 17,060 | $6.50K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 17,259 | $6.58K | 0.00% | +17,259 | New |
| State Street Corp | 25,467 | $9.29K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 30,904 | $11.7K | 0.00% | +20,122+186.6% | Added |
| Geode Capital Management, LLC | 34,338 | $12.0K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 40,000 | $15.2K | 0.00% | −48,889−55.0% | Reduced |
| Virtu Financial LLC | 48,531 | $18.0K | 0.00% | −6,037−11.1% | Reduced |
| Vanguard Group Inc | 61,050 | $23.3K | 0.00% | 00.0% | Unchanged |
| Aaron Wealth Advisors | 100,000 | $38.1K | 0.01% | +100,000 | New |
| IFP Advisors, Inc | 50 | – | – | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −257,866−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −10,031−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −5,168−100.0% | Sold out |
| Pittenger & Anderson Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |